Related Experiment Video
Updated: Feb 16, 2026
12:09
Yeast Luminometric and Xenopus Oocyte Electrophysiological Examinations of the Molecular Mechanosensitivity of TRPV4
Published on: December 31, 2013
10.7K
Emerging therapies for atopic dermatitis: TRPV1 antagonists
Jonathan G Bonchak1, Robert A Swerlick1
1Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia.
Journal of the American Academy of Dermatology
|December 18, 2017
Summary
Transient receptor potential TRPV1 channels are key to skin sensations and barrier function. Targeting TRPV1 may offer new treatments for atopic dermatitis, with clinical trials ongoing.
Area of Science:
- Dermatology
- Neuroscience
- Molecular Biology
Background:
- Transient receptor potential (TRP) ion channels mediate somatosensory signaling.
- TRP channels, particularly TRPV1, are increasingly understood for their roles in skin physiology.
- TRPV1 influences pathways involved in itching (pruritus) and skin barrier integrity.
Purpose of the Study:
- To explore the therapeutic potential of targeting TRPV1 in atopic dermatitis.
- To review the role of TRPV1 in pruritus and skin barrier function.
- To examine the relevance of neurokinin antagonists as a related therapeutic strategy.
Main Methods:
- Review of current scientific literature on TRP channels, TRPV1, and atopic dermatitis.
- Analysis of the known physiological functions of TRPV1 in cutaneous pathways.
- Examination of early clinical trial data for related therapies.
Main Results:
- TRPV1 channels are implicated in multiple pathways contributing to pruritus.
- TRPV1 plays a significant role in maintaining the integrity of the skin barrier.
- Neurokinin antagonists target similar pathways and have shown early safety data.
Conclusions:
- TRPV1 is a promising therapeutic target for atopic dermatitis due to its roles in pruritus and skin barrier function.
- Further clinical trials are necessary to establish the efficacy of TRPV1-targeting therapies and neurokinin antagonists in atopic dermatitis.
- Ongoing phase II and III clinical trials will provide crucial data on treatment effectiveness.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.9K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.9K
01:19Antiasthma Drugs: Leukotriene Modifiers
1.9K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.9K
01:43Thermosensation
34.0K
Peripheral thermosensation is the perception of external temperature. A change in temperature (on the surface of the skin and other tissues) is detected by a family of temperature-sensitive ion channels called Transient Receptor Potential, or TRP, receptors. These receptors are located on free nerve endings. Those detecting cold temperatures are closer to the surface of the skin than the nerve endings detecting warmth. These thermoTRP channels, while temperature selective, have relatively...
34.0K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
489
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
489
01:29Inflammatory Bowel Disease IV: Pharmacological Management
795
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
795
01:27Tumor Immunotherapy
2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K